Estradiol valerate/methenmadinone caproate

{{Short description|Combination drug}}

{{Infobox drug

| image = Estradiol valerate.svg

| width = 250px

| caption =

| image2 = Methenmadinone caproate.svg

| width2 = 250px

| caption2 = Estradiol valerate (top) and
methenmadinone caproate (bottom)

| type = combo

| drug_name = Estradiol valerate /
methenmadinone caproate

| component1 = Estradiol valerate

| class1 = Estrogen

| component2 = Methenmadinone caproate

| class2 = Progestogen

| tradename =

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration = Intramuscular injection

| CAS_number = 61829-06-9

| ATC_prefix =

| ATC_suffix =

| PubChem =

| DrugBank =

| synonyms = EV/MMC; Lutofollin

}}

Estradiol valerate/methenmadinone caproate (EV/MMC), known by the tentative brand name Lutofollin, is a combination medication of estradiol valerate (EV), an estrogen, and methenmadinone caproate (MMC; superlutin caproate), a progestin, which was developed for potential use as a once-a-month combined injectable contraceptive but was never marketed.{{cite journal | vauthors = Stĕrba R | title = Tschechoslowakisches Injektionskontrazeptivum, einmal im Monat zu verabreichen | trans-title = A Czechoslovak injection-contraceptive agent administered once a month | journal = Zentralblatt für Gynäkologie | language = de | date = January 1976 | volume = 98 | issue = 3 | pages = 158–160 | issn = 0044-4197 | pmid = 970015 }}{{citation | author = Mokhtar K. Toppozada | title = Monthly Injectable Contraceptives | year = 1983 | url = https://www.researchgate.net/publication/12282789}}{{cite journal | vauthors = Toppozada MK | title = Existing once-a-month combined injectable contraceptives | journal = Contraception | volume = 49 | issue = 4 | pages = 293–301 | date = April 1994 | pmid = 8013216 | doi = 10.1016/0010-7824(94)90029-9 }} It contained 10 mg EV and 60 mg MMC in 1 mL oil solution and was intended for administration by intramuscular injection once every 4 weeks.